Lantheus Holdings, Inc. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 92/100
What the filing says
On August 3, 2026, Lantheus entered into a definitive merger agreement with Curium US Holdings LLC. Curium will acquire all outstanding shares at $102.50 per share in cash, plus contingent value rights (CVRs) of up to $12.00 per share tied to product milestones through 2030, for total consideration up to $114.50 per share and ~$8.0 billion enterprise value. The transaction is expected to create a combined radiopharmaceutical diagnostics and therapeutics company serving 70+ countries; the Board unanimously approved the deal.
Why this rating
Transformational M&A event at 186% of company's current market cap; materially alters ownership and corporate structure. Neutral because deal is already announced and priced; no new value creation or destruction in this filing.
Price action (we called it neutral)
at our read · unknown $101.00 | +10 min · unknown $101.00 ▲ 0.00% | +30 min · unknown $100.99 ▼ 0.01% | +1 hr · unknown $101.00 ▲ 0.00% | +4 hrs · unknown $101.00 ▼ 0.00% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.